---
schema_version: "secwatch.filing_event.v1"
accession: "0001396814-25-000011"
form_type: "8-K"
ticker: "PCRX"
cik: "0001396814"
company_name: "Pacira BioSciences, Inc."
filed_at: "2025-01-10T23:59:59+00:00"
generated_at: "2026-05-28T04:45:49.154534+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Pacira preliminary FY2024 revenue $701M (+3.9% YoY); announces 5x30 growth plan

## Summary
- FY2024 total revenue of $701.0M, up from $675.0M in 2023; Q4 EXPAREL $147.7M.
- EXPAREL net sales $549.0M, ZILRETTA $118.1M, iovera° $22.8M for full year.
- Unveils 5x30 plan: treat >3M patients/year, double-digit revenue CAGR, 5pp gross margin improvement by 2030.
- Inducement grants: options for 20,300 shares and RSUs for 30,400 shares at $18.40.
- Revenue preliminary and unaudited; full Q4 and FY results with guidance expected Q1 2025.

## SEC filing metadata
- accession: 0001396814-25-000011
- form_type: 8-K
- ticker: PCRX
- cik: 0001396814
- company_name: Pacira BioSciences, Inc.
- filed_at: 2025-01-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1396814/000139681425000011/0001396814-25-000011-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1396814/000139681425000011/pcrx-20250110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001396814-25-000011
- JSON: https://secwatch.observer/filing/0001396814-25-000011.json
- Plain text: https://secwatch.observer/filing/0001396814-25-000011.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.